Research progress of antiviral treatment for patients with chronic hepatitis B combined with metabolic fatty liver disease
10.3760/cma.j.cn501113-20231228-00305
- VernacularTitle:慢性乙型肝炎合并代谢功能障碍相关脂肪性肝病患者的抗病毒治疗研究进展
- Author:
Yue CHEN
1
;
Wenkang GAO
;
Jin YE
;
Ling YANG
Author Information
1. 华中科技大学同济医学院附属协和医院消化内科，武汉 430022
- Keywords:
Chronic hepatitis B;
Metabolic fatty liver disease;
Host metabolism;
Complete virologic response;
Nucleos(t)ide analogues;
Epidemiology;
Therapy;
Prognosis
- From:
Chinese Journal of Hepatology
2024;32(10):955-960
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B (CHB) mainly causes cirrhosis and hepatocellular carcinoma (HCC). Metabolic fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide with the continuous changes in lifestyle and dietary patterns and the increase in the number of obese individuals. Consequently, the incidence rate of CHB combined with MAFLD is rapidly increasing. However, the pathogenesis, treatment, and clinical prognosis remain unclear due to the interaction between CHB and MAFLD. Notably, in the academic community, there are still controversies as to whether patients with CHB and MAFLD should immediately start antiviral treatment, whether MAFLD affects the antiviral efficacy in CHB patients, and whether nucleos(t)ide analogues (NAs) affect the body's metabolism. This article reviews the epidemiology, clinical prognosis, treatment management strategies (especially the antiviral efficacy of NAs drugs), and NAs drug effects on the body's metabolism in patients with CHB combined with MAFLD so as to provide diagnostic and therapeutic concept for clinicians.
